[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mahidol University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":696},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,70,0,25,[9,39,70,100,128,161,192,214,245,270,297,322,345,374,401,428,456,481,508,531,560,587,616,647,668],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100053342","diagnostic-value-of-digital-infrared-thermographic-imaging-in-diagnosing-carpal-tunnel-syndrome-100053342",false,"NCT07699289","Diagnostic Value of Digital Infrared Thermographic Imaging in Diagnosing Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* 18 years old or more\n* Were referred to the department of rehabilitation for electrodiagnostic evaluation of the disease not involved in the index hand\n* The hand of interest has cumulative score of less than 12 from CTS-6 scale\n\nExclusion Criteria:\n\n* History of hand surgery in the index hand\n* Having a condition which may alter surface temperature of the hand, for example, infection, scar in the interested area, arthritis, other peripheral neuropathy, uncontrolled diabetes mellitus, uncontrolled thyroid disease, stroke, and vascular disease\n* Having hand deformities that render collecting DITI information to calculate the parameters of interest impossible, for example, amputation of any part of the hand\n* Current medication affecting sympathetic tone\n* Severe tremors or inability to maintain standardized positioning\n* Electrodiagnosis result other than normal or carpal tunnel syndrome in the hand of interest",true,"ALL","18 Years",{"count":20,"type":21},144,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this observational study is to evaluate skin temperature patterns measured by infrared thermography in patients with carpal tunnel syndrome (CTS). The main questions it aims to answer are: Are skin temperature patterns associated with CTS as determined by 6-item CTS scale?\n\nParticipants diagnosed with CTS as part of their routine clinical care will undergo infrared thermal imaging and electrodiagnostic evaluation according to the study protocol. The relationship between thermographic findings and electrodiagnostic severity will be analyzed.",[26],"Carpal Tunnel Syndrome (CTS)","NOT_YET_RECRUITING","2026-07-07",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":21},"2026-09-01",{"date":35,"type":21},"2027-11-30",{"name":37,"class":38},"Mahidol University","OTHER",{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100053935","phase-2-steroid-sparing-regimen-with-olanzapine-and-palonosetron-for-emetic-prevention-for-high-dose-cisplatin-100053935","NCT07699276","Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin","Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study","Inclusion Criteria:\n\n* histologically confirmed solid malignancy\n* scheduled for first cycle of cisplatin at dosage of at least 50 mg\u002Fm2\n\nExclusion Criteria:\n\n* pregnancy\n* pelvic or abdominal radiation within 4 weeks\n* uncontrolled brain metastasis\n* other moderate or high emetic risk chemotherapy on day 2-5\n* untreated gut obstruction\n* known allergy or severe adverse effect from palonosetron or olanzapine\n* AST\u002F ALT \\> 2.5x or serum creatinine clearance less than 50 ml\u002Fmin",{"count":47,"type":21},95,"INTERVENTIONAL",[50],"PHASE2","A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting",[53,54,55,56],"Cancer (Solid Tumors)","Vomiting","Cisplatin","Olanzapine",[58,59,60,61],"cisplatin","chemotherapy induced nausea vomiting","dexamethasone sparing","olanzapine","RECRUITING",{"date":30,"type":31},{"date":65,"type":31},"2026-02-10",{"date":67,"type":21},"2027-11-15",{"name":37,"class":38},1,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":48,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":69},"100644259","pilates-for-sedentary-individuals-100644259","NCT07666919","Pilates for Sedentary Individuals","Efficacy of Pilates on Core Stability and Physical Fitness Among Sedentary Individuals","Inclusion Criteria:\n\n* Aged between 18 and 59 years.\n* Had a Body Mass Index (BMI) of ≥ 23 kg\u002Fm2.\n* Engaged in sedentary activities (sitting) for more than 7 hours per day.\n* Passed the Physical Activity Readiness Questionnaire (PAR-Q) assessment.\n* Did not currently participate in any other exercise programs or physical activities during the study period.\n\nExclusion Criteria:\n\n* Had visual impairments that could not be corrected with corrective lenses or glasses.\n* Had a medical history of spinal or lower extremity surgery.\n* Had medical conditions or received medications that affected balance and gait, such as neurological diseases or benign paroxysmal positional vertigo (BPPV).\n* Pregnant during the study period.\n* Had severe pain in any part of the body (pain score ≥ 7\u002F10).\n* Inability to follow the research procedures.","59 Years",{"count":79,"type":21},34,[81],"NA","The global rise in physical inactivity represents an escalating public health crisis, with the proportion of insufficiently active adults projected to reach 35% by 2030. Office workers are at the highest risk due to prolonged occupational sitting; a lifestyle factor heavily linked to various musculoskeletal disorders. While maintaining an upright posture relies on the synergistic coordination of deep core muscles, extended sitting disrupts this muscular balance, leading to chronic postural decay. Although Pilates is proven to improve core muscle thickness, enhance physical fitness, and alleviate low back pain, existing literature shows high variability in training durations (ranging from 6 to 16 weeks) and lacks definitive conclusions regarding its long-term, residual effects post-intervention. Consequently, it remains unclear whether the benefits of Pilates can be sustained once the structured training stops. Therefore, this study aimed to investigate the efficacy of Pilates on core stability and physical fitness among sedentary individuals, providing insights into sustainable exercise interventions.",[84,85],"Sedentary Behaviors","Core Muscle Weakness",[87,88,89,90,91],"core muscle","core stability","physical inactivity","pilates","sedentary behaviors","2026-06-23",{"date":94,"type":31},"2026-06-26",{"date":96,"type":21},"2026-08",{"date":98,"type":21},"2027-12",{"name":37,"class":38},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":107,"maxAge":18,"enrollmentInfo":108,"targetDuration":4,"studyType":48,"phases":110,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":69},"100643889","artificial-intelligence-based-postural-feedback-for-scoliosis-100643889","NCT07669428","Artificial Intelligence-Based Postural Feedback for Scoliosis","The Effect of Artificial Intelligence-Based Postural Feedback on Posture Correction in Idiopathic Scoliosis Patients","Inclusion Criteria:\n\n* Diagnosis of adolescent idiopathic scoliosis (AIS) by a physician.\n* Aged between 10 and 18 years.\n* Cobb angle between 10 and 40 degrees.\n\nExclusion Criteria:\n\n* Leg length discrepancy greater than 2 cm, measured from the anterior superior iliac spine (ASIS) to the lateral malleolus.\n* Previous history of spinal surgery.\n* Musculoskeletal or neurological injuries that affect balance and gait.\n* Inability to follow the research procedures.","10 Years",{"count":109,"type":21},30,[81],"Due to advancements in technology, Posture-Analyzing and Virtual Reconstructing (PAViR) systems were developed. They used Red-Green-Blue-Depth camera sensors and artificial intelligence to evaluate human posture alignment, muscle balance, and movement without the use of radiation or physical markers. This technology served as a portable, X-ray-like device that was safe and user-friendly, providing detailed views of bone and muscle models alongside easy-to-understand 3D visualizations. However, how to utilize the data obtained from PAViR to support traditional treatment remained unclear. To fill this gap, this study aimed to investigate the effects of AI-based postural feedback on posture correction in patients with idiopathic scoliosis.",[113,114],"Postural Alignment","Idiopathic Adolescent Scoliosis",[116,117,118,119],"artificial Intelligence","posture","scoliosis","three-dimensional imaging","2026-06-22",{"date":122,"type":31},"2026-06-25",{"date":124,"type":21},"2026-07",{"date":126,"type":21},"2027-07",{"name":37,"class":38},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":48,"phases":137,"briefSummary":138,"conditions":139,"keywords":147,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":160,"locationsCount":69},"100641870","brief-bronchial-suction-for-lung-collapse-during-uniportal-vats-100641870","NCT07660588","Brief Bronchial Suction for Lung Collapse During Uniportal VATS","Effect of Brief Bronchial Suction on the Quality of Non-Ventilated Lung Collapse and Time to Adequate Surgical Exposure During Uniportal Video-Assisted Thoracoscopic Surgery: a Randomized Patient- and Surgeon-Blinded Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* BMI ≤ 35 kg\u002Fm2\n* American Society of Anesthesiologists (ASA) physical status I to III\n* Scheduled for elective single-port video-assisted thoracoscopic surgery (VATS) at Siriraj Hospital\n* Requirement for one-lung ventilation using a double-lumen tube (DLT)\n* Surgery performed in the lateral decubitus position\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Previous thoracic surgery\n* Known or suspected severe pleural adhesions based on preoperative imaging or clinical history\n* Tracheobronchial anatomical abnormalities\n* Pulmonary bullae identified on chest radiography or computed tomography, or a history of recurrent pneumothorax\n* Forced vital capacity (FVC) \\\u003C 50% of predicted\n* Pregnancy",{"count":136,"type":21},100,[81],"The goal of this clinical trial is to learn whether a brief suction of the airway going to the surgical lung (bronchus) can help the lung collapse faster and more completely during uniportal video-assisted thoracoscopic surgery (UVATS). This type of surgery is performed through a small incision in the chest, and good lung collapse helps the surgeon see and work safely. The main questions it aims to answer are\n\n1. Does brief bronchial suction improve the quality of lung collapse 1 minute after chest cavity is opened?\n2. Does brief bronchial suction help reach satisfactory lung collapse faster?\n\nResearchers will compare patients who receive brief bronchial suction and those who do not. This is to see if suction improves and fastens lung collapse, reduce the need for additional steps if lung is not adequately collapsed, affect inflammation, oxygenation, postoperative pulmonary complications, operative time, and the duration of one-lung ventilation. Participants will\n\n1. Undergo UVATS under general anesthesia\n2. Have a double-lumen breathing tube placed as part of the standard anesthetic care\n3. Be randomly assigned to either receive bronchial suction for one minute or receive no bronchial suction\n4. Have the surgical team assess the quality of lung collapse at different time points\n5. Have blood samples taken for interleukin-6, a marker related to inflammation, once during and once after surgery. These samples are collected through a small tube in a vein that is placed as a standard anesthetic care while the participant is under general anesthesia. No extra puncture is required for blood collection.\n6. Have information collected from the routine anesthesia and surgical records such as oxygen levels during surgery, length of surgery and lung-related complications within 7 days after surgery",[140,141,142,143,144,145,146],"Lung Collapse","One-lung Ventilation","Thoracic Anesthesia","Thoracic Surgery, Video-assisted","Double-lumen Tube","Uniportal Video Assisted Thoracic Surgery (U-VATS)","Postoperative Pulmonary Complications",[148,149,150,151,152,153,154],"uniportal VATS","UVATS","bronchial suction","lung collapse","one-lung ventilation","double-lumen tube","thoracic anesthesia","2026-06-16",{"date":120,"type":31},{"date":96,"type":21},{"date":159,"type":21},"2028-07",{"name":37,"class":38},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":69},"100637660","development-and-validation-of-the-paediatric-scale-for-quality-of-recovery-in-the-post-anaesthesia-care-unit-100637660","NCT07610915","Development and Validation of the Paediatric Scale for Quality of Recovery in the Post-Anaesthesia Care Unit","Development and Validation of the Paediatric Scale for Quality of Recovery in the Post-Anaesthesia Care Unit (PedSQoR-PACU)","PedSQoR-PACU","Inclusion criteria\n\n* Children aged 8-17 years for self-report version\n* Parents\u002Fcaregivers of children aged 2-7 years for proxy-report version\n* Elective surgery\u002Fprocedure under anaesthesia\n* Planned recovery in PACU\n* ASA I-IV\n* Able to communicate in the prespecified site language (Thai - in Siriraj Hospital site)\n* Informed consent\u002Fassent obtained as applicable Exclusion criteria\n* Unable to communicate in the prespecified site language (Thai - in Siriraj Hospital site)\n* Urgent or emergency surgery\u002Fprocedure\n* Not planned to recover in PACU, including planned direct transfer from theatre to ICU\n* Developmental delay or other condition limiting comprehension for interview participation or questionnaire completion\n* Not available for an uninterrupted interview or questionnaire completion.","2 Years","17 Years",{"count":172,"type":21},200,"This project aims to develop and test a new questionnaire to measure how well children recover in the post-anaesthesia care unit (PACU). Currently, children in PACU are mainly assessed using discharge readiness criteria, but these do not fully capture the child's recovery experience or overall wellbeing. Participants will be children aged 2-17 years having elective procedures requiring anaesthesia or sedation, and their parents\u002Fcaregivers where proxy reporting is needed for younger children. The study will be conducted in stages, including interviews to identify important aspects of recovery, expert review of draft questions, testing of question clarity and acceptability, and field testing of the questionnaire in PACU at planned time points during recovery. Clinical information routinely collected as part of care, such as pain scores, nausea vomiting, airway or oxygen events, and length of stay in PACU, will also be examined to assess how well the questionnaire performs. The expected outcome is a child-centred, practical, and reliable PACU recovery measure that can be used in clinical care, quality improvement, and future research.",[175],"Postoperative Recovery in Children",[177,178,179,180,181,182,183],"Pediatric anesthesia","Postoperative recovery","Patient-reported outcomes","Questionnaire development","Questionnaire validation","Psychometric validation","postanesthesia-care unit","2026-05-20",{"date":186,"type":31},"2026-05-28",{"date":188,"type":21},"2026-06-15",{"date":190,"type":21},"2027-07-31",{"name":37,"class":38},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":200,"targetDuration":202,"studyType":23,"phases":4,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":69},"100622044","thai-version-of-the-pediatric-quality-of-recovery-score-pedsqor-translation-and-psychometric-validation-study-100622044","NCT07378501","Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study","Translation and Psychometric Validation of the Thai Version of the Pediatric Quality of Recovery Score (Thai-PedsQoR)","Thai-PedsQoR","Inclusion Criteria:\n\n* Pediatric patients aged 2-17 years undergoing day surgery\u002Fintervention or surgery\u002Fintervention requiring postoperative hospital admission.\n* ASA Physical Status I-III.\n\nExclusion Criteria:\n\n* Patients or parents\u002Fguardians who are unable to communicate in Thai.\n* Urgent or emergent surgery.\n* Children with significant developmental delay or severe systemic disease that interferes with activities of daily living.\n* Parents, guardians, or patients who, in the opinion of the investigator, are unlikely to be available to complete follow-up.",{"count":201,"type":21},130,"21 Days","Postoperative recovery in children is a complex, multidimensional process that differs substantially from recovery in adults, encompassing physical comfort, emotional well-being, behavioral changes, and psychosocial functioning. While several validated Quality of Recovery (QoR) instruments are widely used in adult perioperative care, equivalent tools for pediatric populations remain limited, particularly in non-English-speaking settings. The Pediatric Quality of Recovery score (PedSQoR) was recently developed to address this gap by providing a comprehensive, patient- and proxy-reported outcome measure specifically designed for children. However, a culturally adapted and psychometrically validated Thai version of this instrument is currently unavailable.\n\nThe primary objective of this study is to translate and culturally adapt the PedSQoR into Thai in accordance with the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines for patient-reported outcome measures. The secondary objective is to evaluate the psychometric properties of the Thai-PedSQoR, including content validity, construct validity, reliability, and responsiveness, in Thai pediatric surgical patients.\n\nThis clinical applied research will be conducted at Siriraj Hospital and will include children aged 2-17 years undergoing elective surgery or procedures requiring anesthesia. The translation process will involve forward and backward translation, expert committee review, and cognitive debriefing with parents and children to ensure conceptual equivalence and cultural appropriateness. Psychometric validation will be performed in a cohort of 130 participants, stratified into proxy-report and self-report groups according to age. The Thai-PedSQoR will be administered on postoperative days 2, 6, and 21, alongside anchor measures including pain and global recovery visual analog scales.\n\nThe expected outcome of this study is a reliable and valid Thai version of the PedSQoR that can be used in clinical practice, quality improvement initiatives, and future pediatric perioperative research, supporting patient-centered and value-based pediatric surgical care in Thailand.",[175],[177,178,179,181,182],"2026-05-15",{"date":208,"type":31},"2026-05-19",{"date":210,"type":31},"2026-05-05",{"date":212,"type":21},"2027-06-30",{"name":37,"class":38},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":48,"phases":223,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},"100636654","greater-occipital-nerve-block-for-migraine-with-medication-overuse-headache-100636654","NCT07568496","Greater Occipital Nerve Block for Migraine With Medication Overuse Headache","GONB_MOH","Inclusion Criteria:\n\n* Patients who have a diagnosis of migraine with medication overuse headache according to ICHD-3 criteria confirmed by a neurologist\n* Female patients will be screened for pregnancy planning and married female patients must undergo a urine pregnancy test\n\nExclusion Criteria:\n\n* Patients who have other types of headache disorders other than migraine\n* Patients who have a previous history of allergy to corticosteroid or lidocaine\n* Patients who had previous skull surgery\n* Pregnant women\n* Patients with a history of uncontrolled depression, or psychosis\n* Patients who get or plan to get CGRP-targeted therapies or botulinum toxin injection\n* Patients with an increased risk of bleeding or underlying bleeding disorders","80 Years",{"count":201,"type":21},[81],"Migraine is among the leading causes of disability worldwide. Inappropriate use of acute medications in the setting of primary headache, particularly migraine can result in a debilitating condition known as medication overuse headache (MOH). Treatment of MOH is challenging and the primary therapeutic approach is reducing painkillers which helps decrease the number of headache days. As a part of the detoxification process to discontinue acute medications, bridging therapy is often needed to reduce withdrawal headache. Currently, there are data supporting the use of greater occipital nerve block as a preventive treatment in chronic migraine, but no placebo-controlled trial has evaluated the efficacy of greater occipital nerve block in MOH. Therefore, this research aims to demonstrate the efficacy of greater occipital nerve block in detoxification of migraine patients with MOH. Patients will be recruited from Headache Clinic at 3 centers in Thailand from February 2026 to January 2028. After recruitment, patients will be randomized into 2 groups at a 1:1 ratio using a block of four, namely group A and B. A 5-mL syringe of 2 mL of lidocaine 2% and 2 mL of methylprednisolone 40 mg\u002FmL (80 mg) will be prepared for each patient in group while a 5-mL syringe of 4 mL normal saline will be prepared for each patient in group B. Monthly headache days, duration, severity, acute medication type and number of usage days and relative headache status according to a 5-point Likert scale will be investigated at the 2 weeks, 1st, 2nd and 3rd month, MIDAS at the end of 3rd month.",[226,227,228],"Migraine Disorders","Medication Overuse Headache","Greater Occipital Nerve Block",[230,231,232,233,234,235],"GONB","Nerve Block","Detoxification","MOH","Methylprednisolone","Lidocaine","2026-05-11",{"date":238,"type":31},"2026-05-13",{"date":240,"type":21},"2026-05-01",{"date":242,"type":21},"2028-11-01",{"name":37,"class":38},3,{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":48,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":267,"leadSponsor":269,"locationsCount":69},"100638344","bis-in-critically-ill-patients-in-icu-100638344","NCT07583732","BIS in Critically Ill Patients in ICU","The Comparison of Bispectral Index Parameter Between Critically Ill Patients With and Without Decreased Mental Status and Its Association With Clinical Outcomes","Inclusion Criteria:\n\n1. Age≥18years\n2. RASS score ≤ -3 as case\n3. RASS score 0 to -1 as control\n4. Expected ICU length of stays ≥ 24hours\n\nExclusion Criteria:\n\n1. Contraindication for BIS monitoring (wound or infection at forehead)\n2. No space for attach BIS monitoring at forehead\n3. Patient with sedative drugs (Propofol, Midazolam, Dexmedetomidine)\n4. Patient with acute stroke\n5. Patient was already on EEG monitoring\n6. Denied by patients or patient's surrogates",{"count":253,"type":21},40,[81],"The Bispectral Index (BIS) is a monitor that converts brain electrical activity from EEG into a simple number from 0 to 100. A higher number means the patient is more awake, while a lower number means deeper sedation or reduced brain activity.\n\nIn general, 100 means fully awake, 80 suggests light to moderate sedation, 60 is commonly used as a target for general anesthesia with a low chance of awareness, 40 indicates deep anesthesia, 20 suggests marked brain suppression with burst suppression on EEG, and 0 indicates no detectable cortical electrical activity.\n\nAlthough BIS was originally developed for use in the operating room, it has also been applied in the ICU to help guide sedation, avoid over- or under-sedation, and assess consciousness in patients who cannot be evaluated reliably using standard clinical scores. BIS has also been studied as a possible tool for predicting outcomes in comatose ICU patients, such as those after cardiac arrest, stroke, encephalitis, or traumatic brain injury. However, evidence is still limited for its use in predicting outcomes among ICU patients with any form of decreased consciousness. Therefore, this study was conducted to explore that role.",[257],"Critically Ill Patients",[259,260,261,262,263],"BIS","processed EEG","ICU patient","Sedation","Neuromonitoring","2026-05-06",{"date":238,"type":31},{"date":206,"type":21},{"date":268,"type":21},"2027-03-31",{"name":37,"class":38},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":277,"targetDuration":4,"studyType":48,"phases":279,"briefSummary":281,"conditions":282,"keywords":288,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":296,"locationsCount":69},"100633097","phase-3-rifaximin-treatment-in-bloating-predominant-functional-bowel-disorders-100633097","NCT07522255","Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders","The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders: A Randomized Double-blind Placebo-Controlled Trial With Gut Microbiota and Intestinal Gas Analysis","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Rome IV diagnosis of irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension.\n* Bothersome bloating with baseline severity of at least 3 on a 7-point Likert scale after adequate constipation treatment, defined as stool frequency from at least 3 times\u002Fweek to 3 times\u002Fday and Bristol Stool Form Scale type 3-5.\n* Colonoscopy, CT colonography, or barium enema performed if clinically indicated as part of standard evaluation for bowel symptoms.\n\nExclusion Criteria:\n\n* History of major gastrointestinal surgery, except appendectomy or laparoscopic cholecystectomy.\n* Inflammatory bowel disease or other inflammatory gastrointestinal conditions.\n* Current use of, or inability to discontinue, medications that may affect intestinal microbiota or gas measurements, including antibiotics, proton pump inhibitors, probiotics, lactulose, NSAIDs, or metformin.\n* Current use of, or inability to discontinue, medications that may affect bloating symptoms, including simethicone, simethicone-containing antispasmodics, or antidiarrheal medications.\n* Underlying conditions known to affect intestinal microbiota composition, including cirrhosis, uncontrolled diabetes mellitus, end-stage renal disease, obesity, malignancy, or psychiatric disorders.\n* Opioid-induced constipation.\n* Known allergy to rifaximin.",{"count":278,"type":21},78,[280],"PHASE3","This randomized, double-blind, placebo-controlled trial will evaluate whether a 14-day course of rifaximin improves bloating in adult patients with Rome IV functional bowel disorders in whom bloating is the predominant symptom. Eligible participants with irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension and bothersome bloating despite adequate bowel movement management will be assigned in a 1:1 ratio to rifaximin 550 mg three times daily or matching placebo for 2 weeks. The primary endpoint is the proportion of participants with bloating response, defined as at least a 1-point reduction from baseline in a 7-point Likert bloating score at the end of treatment.",[283,284,285,286,287],"Bloating","Rifaximin","Functional Bowel Disorder","Irritable Bowel Syndrome","Constipation",[284,283,289],"Functional bowel disorder","2026-04-03",{"date":292,"type":31},"2026-04-13",{"date":294,"type":21},"2026-04",{"date":98,"type":21},{"name":37,"class":38},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":48,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":69},"100606416","phase-2-holy-basil-in-the-treatment-of-dyspepsia-100606416","NCT07175272","Holy Basil in The Treatment of Dyspepsia","Evaluation of The Effect of Holy Basil in The Treatment of Patients With Dyspepsia","Inclusion Criteria:\n\n* Participants aged 18 years and older.\n* Presence of dyspeptic symptoms, assessed by the Leeds Dyspepsia Questionnaire with a score of at least 5 or higher.\n\nExclusion Criteria:\n\n* Presence of Helicobacter pylori infection.\n* Diagnosis of peptic ulcer or erosive esophagitis Los Angeles Classification grade B or greater.\n* Use of acid-suppressant therapy including proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) that cannot be discontinued at least 2 weeks prior enrolment and during the study period.\n* Use of mucosal protective agents, such as rebamipide, sucralfate, or irsogladine that cannot be discontinued at least 4 weeks prior enrolment and during the study period.\n* History of gastric cancer or duodenal cancer.\n* Previous upper gastrointestinal surgery.\n* Current pregnancy or lactation.\n* Known allergic to the medicine.",{"count":305,"type":21},27,[50,280],"The goal of this clinical trial is to evaluate whether holy basil extract can reduce gastric inflammation and improve symptoms in adult patients with dyspepsia.\n\nThe main questions it aims to answer are:\n\n* Does holy basil extract reduce gastric mucosal inflammation as measured by histopathology?\n* Does holy basil extract improve dyspeptic symptoms, endoscopic findings, gastric pH, duodenal eosinophil counts, and systemic inflammation (serum IL-6)?\n\nParticipants will:\n\n* Take 300 mg of holy basil extract orally once daily for 28 days\n* Complete symptom questionnaires and diaries during treatment\n* Undergo upper endoscopy with biopsy and intragastric pH monitoring before and after treatment\n* Provide blood samples for inflammatory marker measurement\n* Be monitored for safety and adverse events",[309],"Dyspepsia and Other Specified Disorders of Function of Stomach",[311,312,313],"Dyspepsia","Gastritis","Holy basil","2026-03-23",{"date":316,"type":31},"2026-03-24",{"date":318,"type":31},"2026-02-13",{"date":320,"type":21},"2026-12",{"name":37,"class":38},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":48,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":4},"100615011","a-single-blind-randomized-controlled-study-comparing-the-efficacy-of-high-intensity-laser-therapy-and-focused-extracorporeal-shock-wave-therapy-in-patients-with-plantar-fasciitis-100615011","NCT07287046","A Single-Blind Randomized Controlled Study Comparing the Efficacy of High-Intensity Laser Therapy and Focused Extracorporeal Shock Wave Therapy in Patients With Plantar Fasciitis","A Comparison of Efficacy Between High-intensity Laser Therapy and Focused Extracorporeal Shock Wave Therapy in Patient With Plantar Fasciitis; Single Blinded Randomize Controlled Study","HILT","Inclusion Criteria:\n\n* Patients aged 18-70 years\n* Pain was worse in the initial step after and an extended period of rest\n* Pain was decreased initially after the first steps but exacerbated with increased activity\n* VAS ≥ 4\n* Pain was localized and sharp but not radiating,\n* Pain was reproduced with palpation of the plantar fascia\n\nExclusion Criteria:\n\n* Have Wound\u002FInfection\u002Ftumor in treatment area\n* History of foot trauma in 3 months\n* History of intervention at plantar fascia in 6 months such as Ultrasound therapy, steroid injection, surgery or botulinum toxin injection\n* Pain medication within one week before participation\n* Patient wasn't desired to participate in the study","70 Years",{"count":332,"type":21},28,[81],"This randomized controlled trial aims to evaluate the efficacy of High-Intensity Laser Therapy (HILT) and Focused Extracorporeal Shock Wave Therapy (fESWT) in reducing pain in patients with plantar fasciitis. The study also examines the effects of HILT and fESWT on health-related outcomes, including VAS-FA, FFI, plantar fascia thickness, and adverse events.\n\nResearchers will compare HILT with fESWT as treatment options for patients with plantar fasciitis.\n\nParticipants will receive either HILT or fESWT along with an exercise program. They will attend follow-up visits to assess outcomes at 1, 2, 3, 6, and 12 weeks after the first treatment.",[336],"Plantar Fasciitis","2026-03-20",{"date":339,"type":31},"2026-03-25",{"date":341,"type":21},"2026-02-28",{"date":343,"type":21},"2027-02-20",{"name":37,"class":38},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":48,"phases":356,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":69},"100630269","effects-of-invisalign-palatal-expander-vs-rapid-palatal-expander-with-facemask-in-growing-class-iii-patients-100630269","NCT07485478","Effects of Invisalign Palatal Expander vs Rapid Palatal Expander With Facemask in Growing Class III Patients","Effects of the Invisalign® Palatal Expander (IPE) vs. Rapid Palatal Expander With Facemask in Growing Skeletal Class III Patients: A CBCT Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients aged between 8 and 12 years\n* Patients in the mixed dentition or early permanent stage have at least three stable teeth per quadrant, good oral hygiene, and healthy periodontal tissues\n* Patients with maxilla-mandibular discrepancies; skeletal class III is indicated by an ANB angle \\\u003C 0 degrees or a Wits appraisal value that is negative, and Maxillary constriction is characterized by posterior crossbite teeth or having a maxillary width below the norm value.\n\nExclusion Criteria:\n\n* Patients with craniofacial anomalies such as cleft lip and palate\n* Patient with a prior history of maxillary expansion.\n* Patients who have systemic conditions that contraindicate orthodontic treatment.","8 Years","12 Years",{"count":355,"type":21},24,[81],"The goal of this clinical trial is to compare two types of palatal expanders used with a facemask in children who have skeletal Class III and a narrow upper jaw. The study will compare the Invisalign Palatal Expander (IPE) and the Rapid Palatal Expander (RPE). Researchers want to learn how these devices affect jaw bones and tooth position. They also want to learn about children's and parents' experiences during treatment.\n\nThe main questions this study aims to answer are:\n\nDo IPE and RPE widen the upper jaw differently?\n\nDo they cause different changes in tooth position?\n\nHow do children and parents describe their treatment experience?\n\nParticipants will be children aged 8 to 12 years who have skeletal Class III and a narrow upper jaw. Children with craniofacial conditions, previous upper jaw expansion, or medical conditions that prevent orthodontic treatment will not take part. Parents and children must give consent before joining the study.\n\nParticipants will:\n\nBe assigned to receive either IPE or RPE\n\nExpand the upper jaw to 7 mm (0.25 mm per day)\n\nAfter expansion, wear a facemask for at least 12 hours per day for 6 to 8 months\n\nHave cone-beam computed tomography (CBCT) scans taken before expansion, after expansion, and after facemask treatment\n\nTake part in an interview with a parent after expansion\n\nResearchers will use CBCT images to measure changes in jaw bones and tooth position. The main outcomes are changes in jaw bones and tooth position. Secondary outcomes include children's and parents' experiences during treatment.",[359,360],"Skeletal Class III Malocclusion","Transverse Maxillary Deficiency",[362,363,364,365,366],"Invisalign Palatal Expander","Rapid Palatal Expansion","Facemask","CBCT","Retrognathic maxilla","2026-03-16",{"date":337,"type":31},{"date":370,"type":21},"2026-03",{"date":372,"type":21},"2027-10",{"name":37,"class":38},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":48,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":69},"100627432","tailored-exercise-to-reduce-aromatase-inhibitor-associated-musculoskeletal-symptoms-100627432","NCT07448558","Tailored Exercise to Reduce Aromatase Inhibitor Associated Musculoskeletal Symptoms","Effectiveness of Tailored Home-based Exercise on Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitor: A Randomized, Controlled Trial","TAILOR-Ex","Inclusion Criteria:\n\n* breast cancer patients with starting adjuvant aromatase inhibitor within 4 weeks\n* able to read and write\n\nExclusion Criteria:\n\n* chronic arthritis\n* history of heart failure or acute coronary syndrome within 6 months\n* individuals who exercises regularly more than 150 minutes\u002Fweek",{"count":383,"type":21},206,[81],"A randomized controlled study evaluating effect of tailored exercise compared to routine practice as a preventive measure of aromatase inhibitor associated musculoskeletal related symptoms in early breast cancer patients",[387],"Patients With Early Breast Cancer Who Initiating Adjuvant Aromatase Inhibitor",[389,390,391,392],"exercise","aromatase inhibitor","musculoskeletal associated symptoms","ิbreast cancer","2026-02-26",{"date":395,"type":31},"2026-03-04",{"date":397,"type":31},"2026-02-18",{"date":399,"type":21},"2029-08-18",{"name":37,"class":38},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":409,"targetDuration":411,"studyType":23,"phases":4,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":69},"100626643","septic-shock-hemodynamic-respond-to-volume-resuscitation-versus-vasopressor-administration-100626643","NCT07438301","Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration","Echocardiographic Assessment the Different of Septic Shock Resuscitation: Comparison of Volume Expansion Versus Vasopressor Administration","ECHO-VEVA","Inclusion Criteria:\n\n* Adult patients aged ≥18 years\n* Diagnosis with Septic Shock (Sepsis-3 Definition of Septic Shock)\n* Hypotension, SBP \\\u003C 90 mmHg, or mean arterial BP \\\u003C 65 mmHg\n\nExclusion Criteria:\n\n* Patients who receive two or more vasopressors\n* Patients who receive inotropic medications\n* Patients who receive simultaneously fluid with vasopressor resuscitation\n* Patients with insufficiently quality ultrasound images for determining echocardiography\n* Patients or their legally authorized representatives (LAR), who decline participation in the study or are unable to provide informed consent before enrollment",{"count":410,"type":21},180,"28 Days","The goal of this observational study is to learn about the change of hemodynamic response from intravenous fluid versus medical (vasopressor) resuscitation by echocardiogram in septic shock patient.\n\nThe main question it aims to answer is:\n\nHow hemodynamic response change from intravenous fluid versus medical (vasopressor) resuscitation by echocardiogram in septic shock patient?\n\nParticipants already receiving the appropriate resuscitation at that time by their medical staff as part of their regular medical care for septic shock. The echocardiogram will assess before and after resuscitation.",[414],"Septic Shock",[416,417,418,419],"sepsis","septic shock","hemodynamic","echocardiogram","2026-02-22",{"date":422,"type":31},"2026-02-27",{"date":424,"type":21},"2026-03-15",{"date":426,"type":21},"2028-01-31",{"name":37,"class":38},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":434,"targetDuration":4,"studyType":48,"phases":436,"briefSummary":437,"conditions":438,"keywords":443,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":69},"100626310","changes-in-hemodynamic-response-following-transcranial-electrical-stimulation-in-sroke-individuals-100626310","NCT07433972","Changes in Hemodynamic Response Following Transcranial Electrical Stimulation in Sroke Individuals","Inclusion Criteria:\n\n1. Unilateral stroke individuals aged 18-80 years.\n2. A first-ever stroke.\n3. Stroke onset from at least 2 weeks-5 years.\n4. Able to walk independently with or without gait aids (modified Rankin scale (mRS) 1-3)\n5. Montreal cognitive Assessment-Thai version (MoCA-T) greater than or equal to 20 scores.\n6. Ability to read, communicate, follow and understand instructions.\n\nExclusion Criteria:\n\n1. Presence of any psychological or neurological antecedent, unstable medical conditions or condition that may increase risk of stimulation such as epilepsy, seizure, and history of brain injury\n2. Having unstable cardiovascular disease or respiratory disease, and uncontrolled chronic disease such as diabetes mellitus (DM), hypertension (HT) and chronic kidney disease (CKD)\n3. Receiving other non-invasive brain stimulation or additional intervention such as TMS, PMS or acupuncture\n4. Presence of metal implantation, intracranial shunt, cochlear implantation, or cardiac pacemakers.\n5. Presence of an opened wound, infectious wound around scalp or craniectomy with unreplaced bone flap\n6. Moderate pain (numeric pain rating score \\> 4\u002F10) in any joint of the upper or lower limb, whether paretic or non-paretic\n7. Presence of color blindness\n8. Presence of any substance use including cannabis and kratom",{"count":435,"type":21},60,[81],"The present study will use transcranial electrical stimulation (tES) which are transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) combined with conventional physical therapy and cognitive-motor dualt ask gait training in sub-acute (at least 2 weeks after stroke onset) to chronic stroke (within 5 years post-stroke) to investigate changes in brain hemodynamics (oxy-hemoglobin and deoxy-hemoglobin concentration) as measured by functional near infrared spectroscopy (fNIRS). The findings may provides insights changes in combining tES with rehabilitation on improvements in brain hemodynamics in sub-acute to chronic stroke.",[439,440,441,442],"Hemorrhagic Stroke","Ischemic Stroke","Subacute Stroke","Chronic Stroke Survivors",[444,445,446,447],"Stroke","functional near-infrared spectroscopy","rehbailitation","transcranial electrical stimulation","2026-02-19",{"date":450,"type":31},"2026-02-25",{"date":452,"type":21},"2026-03-01",{"date":454,"type":21},"2026-12-30",{"name":37,"class":38},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":462,"targetDuration":4,"studyType":48,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":69},"100611102","effects-of-tes-combined-with-cmdt-gait-training-on-cognition-cortical-activity-spinal-motoneuron-excitability-and-motor-performance-in-stroke-individuals-100611102","NCT07236216","Effects of tES Combined With CMDT Gait Training on Cognition, Cortical Activity, Spinal Motoneuron Excitability and Motor Performance in Stroke Individuals","Effects of Transcranial Electrical Stimulation (tES) Combined With Cognitive-motor Dual-task Gait Training on Cortical Activity, Spinal Motoneuron Excitability, Cognition and Motor Performance in Stroke Individuals",{"count":435,"type":21},[81],"The present study will use transcranial electrical stimulation (tES) which are transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) combined with conventional physical therapy and cognitive-motor dual task gait training in sub-acute (at least 2 weeks after stroke onset) to chronic (within 5 years post-stroke) to investigate the effect on cortical activity, spinal motoneuron excitability, cognition and motor performance. The findings may enhance the evidence to support usages of tES for improvimg cognition, motor performance as well as cortical activity and spinal motoneuron excitability in a clinical setting.",[439,440,441,466],"Chronic Stroke Patient",[468,469,470,471,472,473],"stroke","electroencephalography","event related potentials","rehabilitation","gait training","High-definition transcranial electrical stimulation",{"date":475,"type":31},"2026-02-23",{"date":477,"type":31},"2025-12-20",{"date":479,"type":21},"2027-12-30",{"name":37,"class":38},{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":488,"targetDuration":489,"studyType":23,"phases":4,"briefSummary":490,"conditions":491,"keywords":496,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":69},"100624455","international-registry-of-dengue-infection-in-congenital-bleeding-disorders-denguecbdr-100624455","NCT07409857","International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)","DengueCBDR","Inclusion Criteria:\n\nPatients, aged ≥ 1 day old, diagnosed with CBDs (e.g., hemophilia, von Willebrand disease, and other coagulation factor deficiency) who are diagnosed with dengue infection, based on WHO criteria as follow;\n\nClinical dengue infection:\n\nSymptoms of high sustained fever for 3-7 days with 2 of the following: headache, retroorbital pain, myalgia, arthralgia\u002Fbone pain, hemorrhagic manifestation, positive tourniquet test, leukopenia (WBC ≤5000\u002FuL)\n\nProbable dengue infection:\n\nPositive dengue IgM\n\nDefinite dengue infection:\n\nSeroconversion of dengue IgM between acute and convalescent serum OR Rising of dengue IgG (HAI) at least 4 folds between acute and convalescent serum OR Positive NS1 Ag or other dengue-specific antigen tests\n\nDengue hemorrhagic fever:\n\nDengue infection with signs of bleeding (including positive tourniquet test) with platelet count \\\u003C 100,000\u002FuL and with signs of leakage (one of the following):\n\n1. Increase Hct at least 15-20% from baseline\n2. Serum albumin \\\u003C 35 g\u002FL\n3. Presence of pleural effusion or ascites\n\nDengue shock syndrome:\n\n1. Narrow pulse pressure (\\\u003C 20 mmHg)\n2. Hypotension\n3. Signs of poor tissue perfusion\n\nSeverity of DHF:\n\n* Grade I: Positive tourniquet test\n* Grade II: Spontaneous bleeding\n* Grade III: Circulatory failure (narrow pulse pressure ≤20 mmHg, hypotension, or signs of poor tissue perfusion)\n* Grade IV: Profound shock with undetectable blood pressure\n\nExclusion Criteria:\n\n* Patients with CBDs with dengue infection who are not willing to participate in the study",{"count":136,"type":21},"14 Days","Dengue fever, a viral infection transmitted by Aedes mosquitoes, is a major health issue in tropical and subtropical regions. Around 20-30% of symptomatic patients developed Dengue Hemorrhagic Fever (DHF), which leads to impaired hemostasis, subsequently increasing the risk of bleeding.\n\nThe hemostatic abnormalities associated with dengue infection included vascular permeability, platelet dysfunction, and coagulation defects. Therefore, Individuals with underlying bleeding disorders are at increased risk of bleeding. Dengue infection in patients with hemophilia was reported, including six of 843 patients in the cohort with underlying hemophilia: five with hemophilia A and one with hemophilia B. Replacement therapy was more commonly used in patients with bleeding disorders and dengue than in patients with other febrile illnesses. All of them had bleeding during dengue infection. The mortality rate was high at 16%.\n\nDespite the importance of this issue, there is a lack of registries or data-collection systems to determine the bleeding complications, the requirement for replacement therapy, and the outcome of dengue infection in congenital bleeding disorders (CBDs). Therefore, this research aims to establish a registry of dengue infections among individuals with CBDs.\n\nThe study is a multicenter, retrospective study from 1 January 2015 to 31 December 2025 and a prospective cohort study involving hospitals that treat individuals with CBDs and dengue. The registry format will be provided using REDCap system.",[492,493,494,495],"Dengue Disease","Dengue Haemorrhagic Fever","Dengue Fever","Dengue Fever With Warning Signs",[497,498,499],"Dengue","Congenital bleeding disorders","Replacement","2026-02-12",{"date":502,"type":31},"2026-02-17",{"date":504,"type":31},"2025-12-01",{"date":506,"type":21},"2030-12-31",{"name":37,"class":38},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":516,"conditions":517,"keywords":521,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":69},"100624457","association-between-slow-wave-activity-and-sleep-inertia-100624457","NCT07409883","Association Between Slow Wave Activity and Sleep Inertia","Association Between Slow Wave Activity and Sleep Inertia in Nighttime Simulated Naps: An Observational Study With Nap Intervention","Inclusion Criteria:\n\n1. Age between 18 and 60 years\n2. History of appropriate sleep duration at least 6 hours\u002Fnight for a minimum of 2 weeks assessed by sleep diary before the trial\n\nExclusion Criteria:\n\n1. STOP-BANG ≥3 or previous diagnosis of obstructive sleep apnea\n2. Presence of restless legs syndrome as assessed with IRLSSG criteria\n3. Presence of depression as assessed by HADS (Exclude participants with HADS-Depression sub-scale score ≥8 (possible depression)\n4. History of irregular work hours or shift work within 2 weeks\n5. Use of sedative\u002Fhypnotic medications on a regular-basis (3 days\u002Fweek or above)\n6. History of epilepsy and brain tumor",{"count":332,"type":21},"Observational study:\n\nThe goal of this observational study is to learn about the association between slow wave activity before awakening and post-awakening psychomotor vigilance task in time-fixed, 2-hour, simulated night naps in healthy individuals.\n\nThe main question aims to answer is:\n\nIs the quantity of slow wave activity immediately before awakening associated with post-awakening psychomotor vigilance task metrics when awakened after 2-hour nap at night?",[518,519,520],"Sleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization","Sleep Inertia","Night Shift Work",[522,523],"sleep inertia","nap","2026-02-06",{"date":318,"type":31},{"date":527,"type":21},"2026-02-04",{"date":529,"type":21},"2026-08-30",{"name":37,"class":38},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":538,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":48,"phases":541,"briefSummary":542,"conditions":543,"keywords":546,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":69},"100622929","enabling-patient-reported-outcomes-through-innovative-care---acs-epic-acs-100622929","NCT07390006","Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS)","Enabling Patient-Reported Outcomes Through Innovative Care Approach in Thai Older Adults Post-Acute Coronary Syndrome: A Mixed Methods Experimental Design","Inclusion Criteria:\n\nInclusion Criteria for the quantitative phase:\n\n1. Aged ≥ 60 years old.\n2. Diagnosed with ACS and received PCI within 3-12 months.\n3. Being familiar with using a smartphone or tablet with the LINE application, either personally or through a caregiver or family member.\n4. No cognitive impairment assessed by the 6-Item Cognitive Function Test-Thai Version (6CIT), score less than 8.\n5. Able to communicate in the Thai language by speaking, listening, reading, and writing in Thai sufficiently.\n6. Voluntarily agreed to participate and has signed the informed consent form.\n\nInclusion Criteria for the qualitative phase:\n\n1. Participate in the experimental group and complete the program.\n2. Extreme case sampling involves selecting the top 6 highest and top 6 lowest scores for healthy behavior.\n3. Willing to participate in a one-on-one in-depth interview.\n\nExclusion Criteria:\n\nExclusion Criteria for the quantitative phase:\n\n1. Have clinical contraindications to physical exercise (i.e. unstable angina, uncontrolled arrhythmias, systolic \\>180 mmHg or diastolic \\>110 mmHg, an LVEF of less than 40%, recent major surgery within 12 weeks such as CABG, valve replacement, or orthopedic surgery), or any serious medical condition that the cardiologist considers unsafe to perform physical activity.\n2. Visual or hearing impairments that cannot be adequately managed with medical devices (e.g., eyeglasses or hearing aids) and that interfere with the ability to participate in study activities or communicate effectively.","60 Years",{"count":540,"type":21},80,[81],"This study evaluates the effectiveness of an innovative care approach that integrates face-to-face education, motivational counseling, and mobile health (mHealth) support delivered via the LINE application among Thai older adults following acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). The intervention aims to support post-discharge recovery by promoting healthy behaviors, improving health status, and enhancing patient satisfaction with care.\n\nThe primary objective is to assess the effect of the intervention on patient-reported outcomes, including healthy behaviors, health status, and patient satisfaction. Secondary objectives include evaluating unplanned hospital visits during a 12-week follow-up period and exploring participants' experiences, motivation, and engagement with the innovative care approach.",[544,545],"Acute Coronary Syndrome\u002F Myocardial Infarction","Coronary Artery Disease",[547,548,549,550,551],"Acute Coronary Syndrome","Mobile Health","Nurse-led Counseling","Patient Reported Outcome","Older Adult","2026-02-05",{"date":554,"type":31},"2026-02-09",{"date":556,"type":21},"2026-03-10",{"date":558,"type":21},"2027-01-10",{"name":37,"class":38},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":567,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":48,"phases":569,"briefSummary":571,"conditions":572,"keywords":576,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":4},"100624266","phase-4-lemborexant-for-sleep-and-delirium-prevention-in-elderly-icu-patients-100624266","NCT07407400","Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients","Lemborexant for Sleep Promotion and Delirium Prevention in Critically Ill Adults: A Combined Feasibility-Pilot, Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Age 65 years or older.\n* Admission to the Surgical Intensive Care Unit (SICU).\n* Anticipated ICU stay of at least 48 hours, as assessed by the ICU consultant and responsible surgeon.\n* Able to receive enteral medication via oral or nasogastric route.\n\nExclusion Criteria:\n\n* Requirement for frequent neurological checks or scheduled awakening (e.g., acute stroke or neurosurgery).\n* Deep sedation defined as Richmond Agitation-Sedation Scale (RASS) ≤ -3.\n* Positive Confusion Assessment Method for the ICU (CAM-ICU) within 12 hours prior to randomization.\n* Severe hemodynamic or respiratory instability requiring neuromuscular blockers or high-dose vasopressors (e.g., norepinephrine ≥ 0.1 µg\u002Fkg\u002Fmin and titrating upward).\n* High risk of aspiration, including ongoing vomiting, gastric residual volume \\>250 mL, or intolerance to oral or enteral medications.\n* Concomitant use of strong CYP3A inhibitors or inducers (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, rifampicin, carbamazepine, phenytoin, or St. John's wort).\n* Severe hepatic impairment (Child-Pugh class C).\n* End-stage kidney disease or chronic kidney disease stage 5.\n* Concomitant use of sedative-hypnotic medications, including benzodiazepines, Z-drugs, trazodone, tricyclic antidepressants, melatonin, or other sleep-inducing agents.\n* Known hypersensitivity to lemborexant or other dual orexin receptor antagonists.\n* History of cataplexy-like symptoms or severe depression with suicidal ideation.","65 Years",{"count":136,"type":21},[570],"PHASE4","Sleep disturbance is very common among critically ill patients in the intensive care unit (ICU), particularly in older adults after surgery. Poor sleep in the ICU is associated with important complications, including delirium, longer duration of mechanical ventilation, prolonged hospital stay, and increased mortality. Current non-drug approaches to improve sleep, such as reducing noise and light and clustering nursing care, may provide limited benefit and are often difficult to implement consistently. Safe and effective drug treatments for sleep in critically ill older patients remain limited.\n\nLemborexant is a dual orexin receptor antagonist that promotes sleep by blocking wake-promoting pathways in the brain. Unlike many traditional sleep medications, lemborexant has minimal effects on breathing and has been shown to be well tolerated in older adults with insomnia. However, its effects on sleep and delirium have not been studied in critically ill patients.\n\nThis study is a single-center, randomized, double-blind, placebo-controlled feasibility and pilot trial conducted in the surgical intensive care unit of Siriraj Hospital, Bangkok, Thailand. The study will enroll 100 critically ill postoperative patients aged 65 years or older who are expected to remain in the ICU for at least 48 hours. Participants will be randomly assigned to receive either low-dose lemborexant (2.5 mg) or a matching placebo once nightly for three consecutive nights. All participants will also receive standard non-pharmacologic sleep-promoting care used in the ICU.\n\nThe main goals of this pilot study are to evaluate the feasibility and safety of administering lemborexant in elderly ICU patients and to explore its potential effects on sleep and delirium. Sleep will be assessed using both subjective questionnaires completed each morning and objective wrist-worn actigraphy to measure sleep duration and sleep stages. Delirium will be assessed twice daily using a standardized delirium screening tool for up to seven days or until ICU discharge. Additional outcomes include medication adherence, adverse events, duration of mechanical ventilation, length of ICU and hospital stay, and in-hospital mortality.\n\nThe results of this study will provide important preliminary data on the feasibility, safety, and potential benefits of lemborexant in critically ill older adults and will help inform the design of future larger clinical trials aimed at improving sleep and reducing delirium in the ICU.",[573,574,575],"Sleep Disturbance","Delirium","Critical Illness",[577,578,573,574,579,580],"Lemborexant","Dual Orexin Receptor Antagonist","Intensive Care Unit","Critically Ill Elderly",{"date":500,"type":31},{"date":583,"type":21},"2026-04-01",{"date":585,"type":21},"2027-12-31",{"name":37,"class":38},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":48,"phases":596,"briefSummary":597,"conditions":598,"keywords":603,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":615,"locationsCount":69},"100615030","endotracheal-tube-suctioning-versus-no-suctioning-during-emergence-from-general-anesthesia-100615030","NCT07287293","Endotracheal Tube Suctioning Versus No Suctioning During Emergence From General Anesthesia","Comparison of Endotracheal Tube Suctioning Versus No Suctioning During Emergence From General Anesthesia With Endotracheal Intubation: A Randomized, Single-Blind Study","Inclusion Criteria:\n\n* Adults aged 18-90 years with American Society of Anesthesiologists (ASA) physical status I-III.\n* Scheduled for elective surgery under general anesthesia requiring endotracheal intubation.\n* Planned tracheal extubation in the operating room at the end of surgery.\n\nExclusion Criteria:\n\n* Inability to provide informed consent or the presence of a significant language barrier that prevents effective communication with the clinical team.\n* Known diagnosis of obstructive sleep apnea (OSA), active pneumonia, or chronic pulmonary disease (e.g., chronic obstructive pulmonary disease, restrictive lung disease).\n* Body mass index (BMI) \\>35 kg\u002Fm².\n* Pregnancy or increased aspiration risk (e.g., full stomach).\n* Scheduled for maxillofacial, head and neck, or airway surgery.\n* Anticipated surgical duration \\>3.5 hours.\n* Anticipated difficult airway, defined as the presence of ≥2 predictors of difficult mask ventilation (DMV) based on Langeron et al., or a documented history of difficult intubation.",{"count":595,"type":21},408,[81],"The goal of this study is to determine whether omitting tracheal suctioning immediately prior to extubation is non-inferior to routine tracheal suctioning with respect to early postoperative oxygenation among adult surgical patients (aged 18-90 years, American Society of Anesthesiologists \\[ASA\\] physical status I-III) undergoing elective surgery under general anesthesia with endotracheal intubation.\n\nThe study addresses the following questions:\n\n* Primary outcome (non-inferiority):\n* Is the risk of postoperative desaturation (oxygen saturation \\[SpO₂\\] \\\u003C92% within 60 minutes after extubation) in the no-suction group not worse than in the routine-suction group by more than 10 percentage points?\n* Secondary outcomes (superiority):\n* Does omitting tracheal suctioning reduce postoperative cough severity and sore throat?\n* Does omitting tracheal suctioning avoid increasing extubation-related adverse events?\n\nParticipants will be randomly assigned (1:1) to one of two groups:\n\n* Routine suctioning (SUC): Endotracheal suctioning plus oropharyngeal suctioning immediately before extubation\n* No suctioning (NON-SUC): Oropharyngeal suctioning only, without endotracheal suctioning\n\nAll participants will receive standard anesthetic care and postoperative monitoring in the post-anesthesia care unit (PACU) for 60 minutes. Follow-up for airway symptoms and patient satisfaction will be conducted at 24 hours after surgery.",[599,600,601,602],"Hypoxia","Airway Obstruction, Postoperative","Sore Throat","Cough, Postoperative",[604,605,606,599,607,608],"Airway Management","Suctioning","Emergence from Anesthesia","Endotracheal Intubation","Postoperative Complications","2026-01-09",{"date":611,"type":31},"2026-01-12",{"date":613,"type":31},"2026-01-05",{"date":268,"type":21},{"name":37,"class":38},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":16,"sex":17,"minAge":623,"maxAge":624,"enrollmentInfo":625,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":627,"conditions":628,"keywords":631,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":646,"locationsCount":69},"100616749","colour-match-stability-and-patients-satisfaction-of-single-shade-composites-in-anterior-teeth-100616749","NCT07309653","Colour Match, Stability, and Patient's Satisfaction of Single-Shade Composites in Anterior Teeth","Colour Matching, Stability, and Patient's Satisfaction in Maxillary Anterior Restorations Using Single-Shade Composite and Silicone-Guided Index: A 12-Month Clinical Evaluation","Inclusion Criteria:\n\n* Children who exhibit cooperative dental behaviours (rating 3 and 4) according to Frankl's behaviour rating scale (Frankl et al. 1962)\n* Presence of at least one maxillary anterior permanent tooth with one-third of crown structure loss from dental trauma\n* The affected tooth must be vital or have undergone vital pulp therapy (e.g., pulpotomy with Calcium hydroxide, white-MTA, or Biodentine)\n\nExclusion Criteria:\n\n* Known allergy to methacrylate-based materials\n* Presence of parafunctional habits, such as bruxism\n* Presence of rampant caries\n* Presence of signs of hypomineralisation, such as post-eruptive breakdown, hypersensitivity, changes in enamel texture and hardness, and abnormal translucency on radiographs.\n* The affected tooth is classified as having moderate or severe discolouration according to Dean's fluorosis index (Dean, 1942)\n* The affected tooth has lost less than one-third of its coronal crown structure\n* The affected tooth has a fracture located at the subgingival margin\n* The affected tooth requires splinting due to the severity of the trauma\n* Presence of severe malocclusion that could compromise the integrity of the restoration","6 Years","15 Years",{"count":626,"type":21},23,"The goal of this observational study is to evaluate the clinical performance of a single-shade composite resin, used with an injection moulding technique, in restoring maxillary incisors affected by traumatic dental injury in patients aged 6-15 years.\n\nThe main questions it aims to answer are:\n\n* How well does a single composite resin colour match the natural tooth?\n* How stable is the colour over a 6- and 12-month follow-up?\n* How satisfied are the children and parents with the restoration?",[629,630],"Tooth Injuries","Dental Restoration, Permanent",[632,633,634,635,636,637,638],"Patient satisfaction","Color stability","Color matching","Single shade composter resins","Injection moulding technique","Flowable composite resins","Dental trauma","2025-12-29",{"date":641,"type":31},"2026-01-02",{"date":643,"type":31},"2025-12-16",{"date":645,"type":21},"2027-10-28",{"name":37,"class":38},{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":17,"minAge":654,"maxAge":221,"enrollmentInfo":655,"targetDuration":4,"studyType":48,"phases":657,"briefSummary":658,"conditions":659,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":666,"leadSponsor":667,"locationsCount":69},"100617509","accelerated-rehabilitation-in-individuals-after-total-knee-arthroplasty-100617509","NCT07319546","Accelerated Rehabilitation in Individuals After Total Knee Arthroplasty","Effectiveness of Accelerated Rehabilitation on Knee Joint Function and Quality of Life in Individuals With Total Knee Arthroplasty: A Double Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients diagnosed with end-stage knee OA necessitating primary unilateral TKA.\n\nExclusion Criteria:\n\n* History of joint infections, cancer, or inflammatory arthritis.\n* End-stage OA from rheumatoid or septic arthritis.\n* Individuals with neurological disorders such as Alzheimer's disease, - Parkinson's disease, stroke.\n* Individuals who are unable to follow a structured rehabilitation protocol.\n* Previous history of knee surgeries (other than arthroscopy).\n* Severe comorbidities that would hinder participation (e.g., advanced cardiovascular diseases).\n* Individuals who have severe osteoporosis.","50 Years",{"count":656,"type":21},32,[81],"The primary aim of this double-blind randomized controlled trial is to evaluate the effectiveness of an accelerated rehabilitation protocol on knee joint function and quality of life in individuals undergoing TKA compared to conventional rehabilitation in Dali, Yunan, China. The study will include patients aged 50-80 years who are scheduled for primary unilateral TKA. Participants will be randomly assigned to either an accelerated rehabilitation group or conventional rehabilitation group. The primary outcomes will include knee joint function, assessed using the KOOS and quality of life measures using the SF-36 surveys. The study will follow participants for 6 months post-surgery to assess longer-term outcomes. This study will not include individuals undergoing revision TKA or those with severe comorbid conditions. The results will provide critical insights into the role of accelerated rehabilitation in improving post-operative recovery, functional outcomes, and overall quality of life for TKA patients.",[660,661],"Knee Osteoarthristis","Arthroplasties, Knee Replacement","2025-12-21",{"date":664,"type":31},"2026-01-06",{"date":504,"type":31},{"date":212,"type":21},{"name":37,"class":38},{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":674,"eligibilityCriteria":675,"healthyVolunteers":12,"sex":17,"minAge":676,"maxAge":677,"enrollmentInfo":678,"targetDuration":4,"studyType":48,"phases":680,"briefSummary":681,"conditions":682,"keywords":684,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":689,"startDateStruct":691,"completionDateStruct":693,"leadSponsor":695,"locationsCount":69},"100616955","impact-of-exercise-derived-extracellular-vesicle-in-blood-and-physical-fitness-data-in-overweightobesity-individuals-100616955","NCT07312344","Impact of Exercise-derived Extracellular Vesicle in Blood and Physical Fitness Data in Overweight\u002FObesity Individuals","Exploring the Impact of Exercise-derived Extracellular Vesicle in Blood and Physical Fitness Data in Overweight\u002FObesity Individuals on Lymphangiogenesis","Exercise","Inclusion Criteria:\n\n1. Male or female individuals aged between 25-45 years\n2. Thai nationality\n3. Ability to walk or perform daily activities independently, without the use of an assistive device\n4. Body mass index (BMI) between 25-35 kg\u002Fm²\n5. Low physical activity levels or sedentary lifestyle based on the World Health Organization 2020\n\n   * The levels of moderate-intensity physical activity \\\u003C 150-300 minutes per week or the levels of vigorous-intensity physical activity \\\u003C 75-150 minutes per week\n   * Moderate-intensity physical activity: fast walking and bicycling. Vigorous-intensity physical activity: running, aerobic dance, and swimming All participants are required to meet all inclusion criteria to be eligible for the research project.\n\nExclusion Criteria:\n\n1. Smoking, substance abuse, or alcohol addiction\n2. History of respiratory diseases, such as asthma, emphysema, or chronic obstructive pulmonary disease\n3. History of cardiovascular diseases, such as coronary heart disease, aortic disease, arrhythmia, or deep vein thrombosis\n4. History of high blood pressure (hypertension)\n5. History of vestibular system diseases, such as Meniere's disease or otitis media\n6. History of neurological disease, such as severe Parkinson's disease or stroke\n7. History of previous lower limb surgery, such as hip, knee, or ankle replacement\n8. History of musculoskeletal diseases, such as severe osteoarthritis\n9. History of severe brain disease, such as dementia\n10. Severe visual or hearing impairment\n11. Have a cognitive and comprehensive impairment and unable to complete the intervention\n12. Have high physical activity or regularly exercise","25 Years","45 Years",{"count":679,"type":21},20,[81],"This project aims to study the effect of exercise in the obesity\u002Foverweight on the changes of physical fitness and blood components. This will provide novel knowledge for medical staffs, researchers, or companies developing alternative strategies for treating obesity\u002Foverweight, including drug development and health promotion project to delay or prevent the onset of the disease.",[683],"Obesity & Overweight",[674,685,686,687,688],"obesity","extracellular vesicle","clinical assessment","physical fitness",{"date":690,"type":31},"2025-12-31",{"date":692,"type":31},"2025-08-30",{"date":694,"type":21},"2026-01-31",{"name":37,"class":38},""]